WHO Model Prescribing Information: Drugs Used in Skin Diseases
(1997; 132 pages) [French] [Spanish] View the PDF document
Table of Contents
View the documentPreface
View the documentIntroduction
Open this folder and view contentsParasitic infections
Open this folder and view contentsInsect and arachnid bites and stings
Open this folder and view contentsSuperficial fungal infections
Open this folder and view contentsSubcutaneous fungal infections
Open this folder and view contentsBacterial infections
Open this folder and view contentsViral infections
Open this folder and view contentsEczematous diseases
Open this folder and view contentsScaling diseases
Open this folder and view contentsPapulosquamous diseases
View the documentCutaneous reactions to drugs
Open this folder and view contentsPigmentary disorders
Open this folder and view contentsPremalignant lesions and malignant tumours
Open this folder and view contentsPhotodermatoses
Close this folderBullous dermatoses
View the documentPemphigus
View the documentBullous pemphigoid
View the documentDermatitis herpetiformis
View the documentAlopecia areata
View the documentUrticaria
Open this folder and view contentsConditions common in children
View the documentAcne vulgaris
View the documentPruritus
View the documentTropical ulcers
Open this folder and view contentsAntimicrobial drugs
Open this folder and view contentsAntifugal drugs
Open this folder and view contentsAntiseptic agents
Open this folder and view contentsKeratoplastic and keratolytic agents
Open this folder and view contentsScabicides and pediculicides
Open this folder and view contentsAnti-inflammatory and antipruritic drugs1
Open this folder and view contentsAntiallergics and drugs used in anaphylaxis
Open this folder and view contentsUltraviolet radiation-blocking agents (sunscreens)
Open this folder and view contentsMiscellaneous drugs
Open this folder and view contentsAnnex
View the documentSelected WHO Publications of Related Interest
View the documentBack cover


Pemphigus vulgaris and a less severe variant, pemphigus foliaceous, in which the blisters are more superficial and the mucous membranes are not involved, are the most common variants of this condition. Occasionally, particularly after exposure to sunlight, the lesions become confluent and lead to a form of exfoliative dermatitis.

Pemphigus vulgaris is typically a disease of middle age. It is most prevalent in eastern India, in southeast Asia and among persons of Jewish descent. Sometimes cases occur after exposure to penicillamine or captopril and associations have also been described with thymoma, myasthenia gravis and other immunopathological conditions. Painful ulcers often develop in the mouth several months before the skin lesions appear. Fragile flaccid blisters develop in the deeper layers of the epidermis in non-inflamed skin, typically on the scalp, chest and intertriginous areas. They extend readily on digital pressure and often rupture, leaving large areas of weeping denuded skin. Ulceration of mucosal surfaces is common and can be extensive. Untreated, most patients die within 5 years from secondary sepsis, electrolyte imbalance and/or emaciation.

Pemphigus vegetans is a variant of pemphigus vulgaris, in which the skin lesions are largely limited to the scalp and intertriginous areas, and appear as crusted papillomatous lesions. However, most cases eventually progress to pemphigus vulgaris.

Brazilian pemphigus or fogo selvagem is a rapidly spreading form of pemphigus, which occurs epidemically in parts of Brazil.


Fluid and electrolyte balance should be carefully monitored. Systemic antimicrobial therapy may be needed for patients with secondary infections.

Compresses soaked in 5% aluminium diacetate, 0.005% silver nitrate, or a 0.01% potassium permanganate solution should be applied to the affected areas every 4 hours. This will facilitate the removal of skin debris from blistered areas and reduce the risk of secondary infection.

High doses of oral corticosteroids are usually required for control. The dose should be gradually reduced once stabilization occurs to the lowest dose that maintains remission. Oral prednisolone or prednisone can be used. Addition of immunosuppressive drugs, such as azathioprine or cyclophosphamide, is often useful when the patient is unable to tolerate the minimum corticosteroid dose that maintains remission. The immunosuppressive effect develops gradually and is usually undetectable until 4-6 weeks after treatment has started. Corticosteroids should be withdrawn before the immunosuppressive drug is discontinued.

to previous section
to next section
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: December 1, 2019